TEGSEDI is the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloidosis in adults. TEGSEDI binds to TTR mRNA to inhibit production of TTR protein.
Contact:
E-mail - Holly.kirkpatrick@interceptpharma.com
E-mail - Aryan.melville@interceptpharma.com
TEGSEDI Prescribing Information »
Featured Content
